NCT06789224View on ClinicalTrials.gov

Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device

NACompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

February 15, 2022

Primary Completion Date

November 25, 2023

Study Completion Date

April 14, 2024

Conditions
Bladder CarcinomaProstate TumorGallbladder CarcinomaEndometrial CarcinomaGastric CarcinomaOvarian CarcinomaPancreatic CarcinomaColon CarcinomaNon-small Cell Lung CancerPeritoneal CarcinomatosisKidney CarcinomaLiver Carcinoma
Interventions
DEVICE

CATUVAB

inducing of aggreation of tumor cells and immune cells via trifunctional antibody and removal of aggregates

Trial Locations (6)

51109

Kliniken der Stadt Köln gGmbH, Cologne

55131

Universitätsmedizin der Johannes Gutenberg-Universität Mainz Klinik für Anästhesiologie, Mainz

60590

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie Universitätsklinikum Frankfurt, Frankfurt

68167

Universitätsmedizin Mannheim, Klinik für Urologie und Urochirurgie, Mannheim

83278

Klinikum Traunstein, Traunstein

97080

Klinik und Poliklinik für Anästhesiologie, Intensivmedizin, Notfallmedizin und Schmerztherapie Universitätsklinikum Würzburg, Würzburg

All Listed Sponsors
lead

Lindis Bloodcare GmbH

INDUSTRY